Automating Ultomiris Prior Authorization for Enhanced Revenue Cycle Efficiency
Klivira streamlines the complex Ultomiris prior authorization process, ensuring timely approvals and reducing administrative burden for your high-volume specialty clinics.
Managing prior authorizations for high-cost, specialty medications like Ultomiris (ravulizumab) presents significant operational challenges, impacting patient access and revenue cycle velocity. The intricate clinical criteria and documentation demands for C5 inhibitor therapies often lead to delays and denials, directly affecting your organization's financial health and patient care pathways.
The Complexities of Ultomiris Prior Authorization
Ultomiris, a critical C5 complement inhibitor, requires rigorous prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans due to its high cost and specific indications (e.g., atypical HUS, gMG, PNH). Navigating payer-specific clinical criteria, documentation for diagnosis confirmation, and evidence of prior therapies demands a precise and often manual workflow, prone to errors and delays.
Key Documentation for Ultomiris PA Submissions
- Confirmed diagnosis (e.g., atypical HUS, gMG, PNH) with supporting laboratory results.
- Clinical notes detailing disease severity, treatment history, and patient response.
- Documentation of prior C5 inhibitor therapy, if applicable (e.g., Soliris).
- Prescribing physician's attestation of medical necessity.
- Patient demographic and insurance information.
Klivira's Intelligent Automation for Ultomiris PA
Klivira leverages AI and machine learning to automate the entire Ultomiris prior authorization workflow, from initiation to approval. Our platform intelligently extracts relevant clinical data from your EMR, matches it against payer-specific rules, and automatically populates X12 278 or ePA forms, significantly reducing manual data entry and improving submission accuracy.
Seamless Integration and Data Exchange
Klivira integrates directly with leading EMR systems via SMART on FHIR and other secure APIs, ensuring a continuous flow of patient data without disruption to clinical workflows. We also establish secure, real-time connections with payer portals and utilize industry standards like NCPDP SCRIPT and Da Vinci PAS to facilitate efficient information exchange and status updates for Ultomiris authorizations.
Operational Benefits for Your Revenue Cycle
- Accelerated Ultomiris PA turnaround times.
- Reduced administrative overhead and staff burden.
- Fewer denials due to incomplete or inaccurate submissions.
- Improved patient access to critical C5 inhibitor therapy.
- Enhanced visibility into PA status across all Ultomiris cases.
- Optimized revenue capture for high-cost specialty drugs.
Ensuring Compliance and Data Security
Klivira operates with robust security protocols, ensuring the confidentiality and integrity of all ePHI involved in the Ultomiris prior authorization process. Our platform is designed with HIPAA compliance as a foundational principle, providing a secure environment for sensitive patient data. Organizations should discuss specific compliance considerations with their internal compliance teams.
Frequently asked questions
How does Klivira adapt to evolving payer criteria for Ultomiris prior authorization?
Klivira's rule engine is continuously updated with the latest payer policies and clinical guidelines for Ultomiris and other specialty drugs. Our system proactively flags potential issues based on real-time criteria changes, ensuring your submissions remain compliant and accurate.
What EMR systems does Klivira integrate with to support Ultomiris PA workflows?
Klivira offers robust integration capabilities with major EMR platforms, including Epic, Cerner, and Meditech, utilizing industry-standard protocols like SMART on FHIR. This ensures seamless data exchange for all Ultomiris prior authorization requirements directly from your existing clinical systems.
Can Klivira manage Ultomiris prior authorizations for Medicare Advantage and Medicaid plans?
Yes, Klivira supports prior authorization workflows across all major payer types, including commercial, Medicare Advantage, and Medicaid managed care plans. Our platform is configured to handle the specific requirements and submission pathways for each, including those for Ultomiris.
How does Klivira handle re-authorization for ongoing Ultomiris therapy?
Klivira automates the re-authorization process by tracking approval expiry dates and proactively initiating new submissions. The system leverages previously submitted data and any updated clinical information from the EMR to streamline subsequent Ultomiris re-authorization requests, minimizing lapses in coverage.
What is the typical implementation timeline for Klivira's Ultomiris PA automation?
Implementation timelines vary based on your organization's specific EMR configuration and integration needs. However, Klivira's modular architecture allows for rapid deployment, often enabling initial Ultomiris prior authorization automation within weeks, with full optimization achieved shortly thereafter.
Related coverage
Automating prior authorization by payer
- Optimizing Aetna Ultomiris Prior Authorization Workflows
- Navigating Anthem (Elevance Health) Ultomiris Prior Authorization
- Navigating Cigna Ultomiris Prior Authorization
- Streamlining Humana Ultomiris Prior Authorization Workflows
- Streamlining Medicaid Ultomiris Prior Authorization Workflows
- Streamlining Medicare Ultomiris Prior Authorization
- Navigating UnitedHealthcare Ultomiris Prior Authorization
Automating prior authorization by specialty
Ready to automate prior auth for this drug?
See how Klivira automates prior authorizations for your team.
Request a demo